Greater Cannabis Company (GCAN) Cash from Investing Activities (2020)
Greater Cannabis Company's (GCAN) quarterly Cash from Investing Activities came in at -$36750.0 in Q4 2020, down 47.0% quarter-over-quarter from -$25000.0 in Q1 2020.
Greater Cannabis Company (GCAN) Cash from Investing Activities (2020) Analysis & Trends
Greater Cannabis Company's Cash from Investing Activities history runs 1 years deep, the most recent figure standing at -$36750.0 for Q4 2020.
- On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to -$36750.0 in Q4 2020; TTM through Dec 2020 was -$61750.0, a N/A change from a year earlier, with the FY2020 full-year figure at -$61750.0, changed N/A from the prior year.
- Cash from Investing Activities slipped to -$36750.0 in Q4 2020 per GCAN's latest filing, from -$25000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$25000.0 in Q1 2020 and bottomed at -$36750.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Greater Cannabis Company | 236,233.75 | 234,794.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -36,750.00 |
| Dec 31, 2020 | -36,750.00 |
| Mar 31, 2020 | -25,000.00 |
| Mar 31, 2020 | -25,000.00 |